The antitumor efficacy of DDR inhibitors has been described in detail above, and the effects on tumor immunity of key ATM/CHK2/P53 pathway and ATR/CHK1/WEE1 pathway inhibitors in DDR, as well as preclinical data of co-inhibition strategies, are reviewed below. This evidence concerns the gene TP53 and neoplasm.